Right or wrong, I choose to believe that the CRO is choosing patients that have "markers" that indicate they are more likely to have success with Multikine. These "markers" may have surfaced in the P2 study. It might be a stretch, but that might be why enrollment is not increasing at an increasing rate. At this point in time, I have to be as optimistic as possible.
The bashers are the #$%$ of the earth. Their motives are selfish and may/may not influence the share price. I have owned shares for well over 10 years and have taken a few dollars off the table but currently am under 40k. By "results", I mean getting a drug to the market place. That is the end game. We will enroll enough patients to be statistically relevant, I hope for cancer patients and my wallet we get approved. Sit back and take it in for a while, we are on the same side, but your constant rebuttals are as annoying as the bashers. I actually have you on ignore as well. We will know soon enough who is right and who is wrong. Take care.
Yank, Long time holder here. The "REAL" killer is not the non stop attacks. It is the lack OF RESULTS. Plain and simple. It's one thing to believe, it's another to be a blow hard. Sit back and #$%$ until Multikine gets approved or we all lose our butts!
You want help? Sell your shares and leave this message board. Pretty simple.
Very true. September will be key. Let's hope they sandbagged a few for September knowing August was pitiful. Bashers have plenty of ammo.
IF the tumors are shrinking after MK dosage, which would presumably make surgical removal easier and more effective, could MK get fast tracked even if stated end points have not yet been met? Please bashers, answer the question with some objectivity. I realize you think this company is a joke. The question is "IF".........